One-year outcomes with mavacamten in a real-world nationwide hypertrophic cardiomyopathy cohort: safety and efficacy

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Cardiac myosin inhibition in hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology